Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Market Leadership | Edwards Lifesciences dominates the TAVR market with robust growth, while expanding into promising TMTT segment with ambitious $2 billion sales target by 2030 |
Financial Health | Strong financials with 79.5% gross margins and 8.23% revenue growth. Analysts project double-digit EPS growth and margin expansion from 2026 onwards |
Regulatory Catalysts | Potential NCD changes could significantly boost TAVR adoption. FDA approval for asymptomatic aortic stenosis treatment may drive market expansion |
Analyst Perspectives | Price targets range from $80 to $90, reflecting confidence in growth potential. Analysts highlight TMTT and new market segments as key drivers |
Metrics to compare | EW | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEWPeersSector | |
---|---|---|---|---|
P/E Ratio | 32.5x | −7.5x | −0.5x | |
PEG Ratio | 0.17 | −0.40 | 0.00 | |
Price/Book | 4.4x | 4.0x | 2.6x | |
Price / LTM Sales | 8.1x | 4.2x | 3.3x | |
Upside (Analyst Target) | 9.1% | 63.6% | 40.6% | |
Fair Value Upside | Unlock | 11.1% | 5.3% | Unlock |